That's the initial consideration. After later reports from the parent company showed that sales for FY17 would be $US700 to $US750, the purchase agreement let Hikma renegotiate the cash upfront down by $US550m... from I think the initial agreement of $1.1B.
So final price for Roxanne was $2.1B, at operating margin of 35% like you quoted up there, that's EBIT of .35*700 = $US245m, or 8.6 P/EBIT.
Maybe paid practically $AUD1B [when you include the transaction, working capital, technical transfer] for a portfolio with FY17 sales of $US237m. EBITDA margin at 50% [they reckon] put earnings at $US118.5.
At current exchange rate, that's price of $US780m to $US118.5 or 6.58.
So it's cheaper on that PE measure. Here's the BUT...
Hikma's purchase only dilute its ownership b 16.7% compare to Mayne's issuing the equivalent of some 80% of existing shares.
Hikma immediately become the top 6 generic company vs Mayne's top 25.
Pipeline potentials of some US41b vs $US7b.
Get the labs, the R&D team and continued shared interests from the seller.
- Forums
- ASX - By Stock
- MYX
- Fundamentals Are Strong
Fundamentals Are Strong, page-38
-
-
- There are more pages in this discussion • 834 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MYX (ASX) to my watchlist
|
|||||
Last
$4.81 |
Change
0.430(9.82%) |
Mkt cap ! $409.2M |
Open | High | Low | Value | Volume |
$4.44 | $4.81 | $4.44 | $1.701M | 362.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 115 | $4.79 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.81 | 6332 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 115 | 4.790 |
1 | 115 | 4.780 |
1 | 115 | 4.770 |
1 | 115 | 4.760 |
2 | 1413 | 4.750 |
Price($) | Vol. | No. |
---|---|---|
4.810 | 6332 | 3 |
4.830 | 34500 | 1 |
4.850 | 2514 | 4 |
4.860 | 115 | 1 |
4.870 | 1413 | 3 |
Last trade - 16.10pm 26/08/2024 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |